Rickets clinical trials at UCSF
2 in progress, 1 open to eligible people
Rickets is a condition that makes bones weak during growth. UCSF is leading a first-in-human test of a new drug for adults with X-linked hypophosphatemia. Researchers collect safety data and measure bone and phosphate outcomes.
First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
open to eligible people ages 18-65
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
San Francisco, California and other locations
X-linked Hypophosphatemia Disease Monitoring Program
Sorry, in progress, not accepting new patients
The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.
San Francisco, California and other locations
Our lead scientists for Rickets research studies include Farzana Perwad, MD Anthony Portale.
Last updated: